Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
Year: 2020
Type: review
Study design: Systematic Review
Abstract: Objective To review and appraise the validity and usefulness of published and preprint reports of prediction models for prognosis of patients with covid-19, and for detecting people in the general population at increased risk of covid-19 infection or being admitted to hospital or dying with the disease. Design Living systematic review and critical appraisal by the covid-PRECISE (Precise Risk Estimation to optimise covid-19 Care for Infected or Suspected patients in diverse sEttings) group. Data sources PubMed and Embase through Ovid, up to 17 February 2021, supplemented with arXiv, medRxiv, and bioRxiv up to 5 May 2020. Study selection Studies that developed or validated a multivariable covid-19 related prediction model. Data extraction At least two authors independently extracted data using the CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist; risk of bias was assessed using PROBAST (prediction model risk of bias assessment tool). Results 126 978 titles were screened, and 412 studies describing 731 new prediction models or validations were included. Of these 731, 125 were diagnostic models (including 75 based on medical imaging) and the remaining 606 were prognostic models for either identifying those at risk of covid-19 in the general population (13 models) or predicting diverse outcomes in those individuals with confirmed covid-19 (593 models). Owing to the widespread availability of diagnostic testing capacity after the summer of 2020, this living review has now focused on the prognostic models. Of these, 29 had low risk of bias, 32 had unclear risk of bias, and 545 had high risk of bias. The most common causes for high risk of bias were inadequate sample sizes (n=408, 67%) and inappropriate or incomplete evaluation of model performance (n=338, 56%). 381 models were newly developed, and 225 were external validations of existing models. The reported C indexes varied between 0.77 and 0.93 in development studies with low risk of bias, and between 0.56 and 0.78 in external validations with low risk of bias. The Qcovid models, the PRIEST score, Carr’s model, the ISARIC4C Deterioration model, and the Xie model showed adequate predictive performance in studies at low risk of bias. Details on all reviewed models are publicly available at https://www.covprecise.org/ . Conclusion Prediction models for covid-19 entered the academic literature to support medical decision making at unprecedented speed and in large numbers. Most published prediction model studies were poorly reported and at high risk of bias such that their reported predictive performances are probably optimistic. Models with low risk of bias should be validated before clinical implementation, preferably through collaborative efforts to also allow an investigation of the heterogeneity in their performance across various populations and settings. Methodological guidance, as provided in this paper, should be followed because unreliable predictions could cause more harm than benefit in guiding clinical decisions. Finally, prediction modellers should adhere to the TRIPOD (transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) reporting guideline. Systematic review registration Protocol https://osf.io/ehc47/ , registration https://osf.io/wy245 . Readers’ note This article is the final version of a living systematic review that has been updated over the past two years to reflect emerging evidence. This version is update 4 of the original article published on 7 April 2020 ( BMJ 2020;369:m1328). Previous updates can be found as data supplements ( https://www.bmj.com/content/369/bmj.m1328/related#datasupp ). When citing this paper please consider adding the update number and date of access for clarity.
Source: BMJ
DOI: 10.1136/bmj.m1328
Authors: Laure Wynants, Ben Van Calster, Gary S Collins, Richard D Riley, Georg Heinze, Ewoud Schuit, Elena Albu, Banafsheh Arshi, Vanesa Bellou, Marc M J Bonten, Darren L Dahly, Johanna A Damen, Thomas P A Debray, Valentijn M T de Jong, Maarten De Vos, Paula Dhiman, Joie Ensor, Shan Gao, Maria C Haller, Michael O Harhay, Liesbet Henckaerts, Pauline Heus, Jeroen Hoogland, Mohammed Hudda, Kevin Jenniskens, Michael Kammer, Nina Kreuzberger, Anna Lohmann, Brooke Levis, Kim Luijken, Jie Ma, Glen P Martin, David J McLernon, Constanza L Andaur Navarro, Johannes B Reitsma, Jamie C Sergeant, Chunhu Shi, Nicole Skoetz, Luc J M Smits, Kym I E Snell, Matthew Sperrin, René Spijker, Ewout W Steyerberg, Toshihiko Takada, Ioanna Tzoulaki, Sander M J van Kuijk, Bas C T van Bussel, Iwan C C van der Horst, Kelly Reeve, Florien S van Royen, Jan Y Verbakel, Christine Wallisch, Jack Wilkinson, Robert Wolff, Lotty Hooft, Karel G M Moons, Maarten van Smeden
Institutions: Maastricht University, Care and Public Health Research Institute, KU Leuven, Leiden University Medical Center, John Radcliffe Hospital, University of Oxford, NIHR Oxford Biomedical Research Centre, Keele University, Medical University of Vienna, Utrecht University, University Medical Center Utrecht, University of Ioannina, University College Cork, Krankenhaus der Elisabethinen, University of Pennsylvania, St George's, University of London, University of Cologne, University Hospital Cologne, Manchester Academic Health Science Centre, University of Manchester, University of Aberdeen, Centre for Epidemiology Versus Arthritis, Amsterdam Public Health, Amsterdam University Medical Centers, University of Amsterdam, Fukushima Medical University, Imperial College London, Maastricht University Medical Centre, University of Zurich, Humboldt-Universität zu Berlin, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charité – Universitätsmedizin Berlin, Kleijnen Systematic Reviews (United Kingdom)
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, European Commission, ZonMw, Fonds Wetenschappelijk Onderzoek, KU Leuven, Vlaamse regering, Oxford Health NHS Foundation Trust, National Institutes of Health, NIHR Oxford Biomedical Research Centre, NIHR School for Primary Care Research, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, Interreg
Awards: G1087870883, G1987921545, G2306515209, G2608461703, G3450463239, G3587225636, Taking ovarian cancer diagnosis to the next level: differential diagnosis of malignancy type, and added value of advanced data sources such as MRI, proteomics, circulating tumour DNA and circulating tumour cells, Integrated human data repositories for infectious disease-related international cohorts to foster personalized medicine approaches to infectious disease research, G4128464806, G434337789, Improving the measurement and analysis of long-term, patient-centered outcomes following acute respiratory failure, G5278681472, Taking ovarian cancer diagnosis to the next level: evaluation of the decision to operate, the added value of MRI and OMICS markers, and optimal integration to patient care pathways, G5514976981, G5918494183, G6019094550, G6074549254, G6122222817, G8124652532, G8641196675, Translational Global Infectious Diseases Research Center
OpenAlex ID: W3014524604
